Publications (7)25.34 Total impact
-
Article: Minimal Residual Disease after Allogeneic Stem Cell Transplantation: A Comparison Among Multiparametric Flow Cytometry, Wilms Tumor 1 Expression and Chimerism Status (Complete chimerism versus Low Level Mixed Chimerism) in Acute Leukemia.
[show abstract] [hide abstract]
ABSTRACT: ABSTRACT Relapse represents the main cause of treatment failure after allogeneic stem cell transplantation (allo-SCT). The detection of minimal residual disease (MRD) by Multiparametric Flow Cytometry (MFC), chimerism, cytogenetics and molecular analysis may be critical to prevent relapse. Therefore, we assessed the overall agreement among chimerism (Low Level-Mixed Chimerism (LL-MC) vs. Complete Chimerism (CC)), MFC and WT1 mRNA to detect MRD and investigated the impact of MRD obtained from the three methods on the outcome of patients. Sixty-seven fresh BM samples from 24 pts (17 AML , 7 ALL) in complete remission (CR) after allo-SCT were investigated at different time points. A moderate agreement was found among the three techniques investigated. A higher concordance between positive results from MFC (75.0% vs. 32.7%, p=0.010) and WT1 (58.3% vs. 29.1%, p=0.090) was detected among LL-MC rather than CC samples. RFS and OS were found higher in MRD negative patients than in MRD positive patients analyzed with MFC and WT1. Our results discourage the use of low autologous signals as the only marker of MRD and suggest the usefulness of MFC and WT1 RQ-PCR in stratifying patients with respect to risk of relapse.Leukemia & lymphoma 04/2013; · 2.40 Impact Factor -
Article: Morphologically Typical and Atypical B-Cell Chronic Lymphocytic Leukemias Display a Different Pattern of Surface Antigenic Density
[show abstract] [hide abstract]
ABSTRACT: Recent evidences suggest that B-cell chronic lymphocytic leukemia (B-CLL) may have heterogeneous biological and clinical features. Immunological phenotype may be useful for distinguishing these different forms of disease. We used a quantitative flow cytometric approach to analyze the expression of several membrane molecules (CD19, CD20, CD22, CD23, CD11c, CD5, CD79b) commonly used to diagnose and characterize B-CLL in a choort of 84 consecutive B-CLL patients diagnosed according to morphological and immunological findings. We found that morphologically so-called “atypical” B-CLL displayed a significantly higher number of CD20 and CD22 molecules than typical forms. On the other hand, CD19 was found to be more expressed in typical B-CLL, although without reaching statistical significance. Finally, no difference was detected with respect to CD23, CD79b, CD11c and CD5 number of molecules/per cell between typical and atypical B-CLL. Other clinico-biological features, such as surface membrane immunoglobulin density, percentage of CD79b and FMC7 expression, peripheral blood lymphocytosis, trisomy 12 and advanced clinical stages were also found to be more frequent in atypical B-CLL. In conclusion, our data confirm the hypothesis that atypical B-CLL is a disease sustained by more mature B-cells, closely related but, at the same time, clearly distincted from neoplastic cells of typical B-CLL.Leukemia and Lymphoma 06/2009; 42(4):649-654. · 2.58 Impact Factor -
Article: Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.
British Journal of Haematology 06/2008; 142(5):852-3. · 4.94 Impact Factor -
Article: Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia
British Journal of Haematology 05/2008; 142(5):852 - 853. · 4.94 Impact Factor -
Article: Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
[show abstract] [hide abstract]
ABSTRACT: Twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib (1.3 mg/m(2) body surface twice weekly for 2 weeks followed by an interval of 10-12 days) without adjunct of steroids as third line therapy. Three patients died of progressive disease during the first 2 cycles with bortezomib. Eighteen patients received at least 2 cycles and were evaluated for response. According to EBMT criteria, two complete (negative immunofixation) and seven partial (reduction of M-component > 50-75%) remissions were achieved (ITT response rate 42.8%). Duration of response lasted from 2 to 14+ months. Grades 3-4 toxicities (thrombocytopenia, leucopenia, peripheral neuropathy and vasculitis) were observed in seven patients, but no patient interrupted the treatment due to side effects. We conclude that bortezomib alone may induce high quality responses as third line salvage therapy with acceptable toxicity in a significant proportion of homogeneously pre-treated myeloma patients with progressive disease after autologous transplantation and thalidomide.Leukemia Research 03/2006; 30(3):283-5. · 2.92 Impact Factor -
Article: Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.
British Journal of Haematology 12/2003; 123(4):746-7. · 4.94 Impact Factor -
Article: Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr.
[show abstract] [hide abstract]
ABSTRACT: Preliminary reports have suggested that autologous stem-cell transplantation (ASCT) is feasible in elderly patients with acute myeloid leukemia (AML). The objective of this study was to describe the disease characteristics and treatment results from a series of 22 elderly AML patients undergoing ASCT. The median age was 64 yr (range 61-71). Twenty patients were in first complete remission (CR1), two in CR2, and all were in performance status 0-1. The median interval between CR achievement and ACST was 3 months (range 2-5). In 20 cases peripheral blood stem cells were infused, in two bone marrow. All patients had a successful engrafment. One patient (5%) died from transplant-related complications. The median number of days to granulocytes > 500 mm-3 and platelets > 20 000 mm-3 was 11(range 9-15) and 13 (range 9-20), respectively. Non-hematologic toxicity included WHO grade III-IV stomatitis in 32% patients and grade IV nausea and vomiting in one (4.5%). Seven patients had fever of unknown origin, while in 14 a documented infection was diagnosed. Median duration of hospitalization was 31 d (range 16-60). After a median follow-up of 12 months from ASCT, nine patients are alive in continuous CR and 13 died from AML relapse. Median survival from diagnosis and disease-free survival (DFS) was 19 and 14 months, respectively. Our data show that ASCT with a standard conditioning regimen is feasible in AML patients aged more than 60 yr. Toxicity and hemopoietic recovery do not substantially differ from those observed in young adults. DFS and overall survival (OS) duration are encouraging, but a longer follow up is needed on a larger series of patients.European Journal Of Haematology 10/2002; 69(4):200-4. · 2.61 Impact Factor
Top co-authors
Top Journals
Institutions
-
2009
-
IRCCS Ospedale Casa Sollievo della Sofferenza
- Hematology
San Giovanni Rotondo, Apulia, Italy
-
